ArticleDiscover oncology2025
Mendelian randomization analysis reveals the causal relationship between immune cells and leukemia.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Potential Causal Association Between Plasma Lipidomes and Keloid: Analysis from a Two-Sample Mendelian Randomization.Clinical, cosmetic and investigational dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundIncreasing evidence indicates certain types of immune cells are linked to leukemia, but whether this link is causal has remained unclear.
methodsA two-sample Mendelian randomization (MR) analysis was conducted to examine the causal relationship (CR) among 731 immune cell traits and leukemia. The inverse variance weighted (IVW) technique was applied, along with the weighted median and MR-Egger approaches, to analyze the data. The instrumental variables were validated for heterogeneity and pleiotropy using sensitivity analyses.
resultsA total of 58 immune cell traits with CRs with leukemia were identified, of which 15 were considered risk factors for leukemia. The factors were distributed among acute myeloid leukemia (AML) (3 traits), acute lymphoblastic leukemia (ALL) (4 traits), chronic myeloid leukemia (CML) (3 traits), and chronic lymphocytic leukemia (CLL) (5 traits). Additionally, 43 immune traits were considered protective factors for leukemia and were distributed among ALL (15 traits), AML (9 traits), CLL (18 traits), and CML (1 trait). After FDR correction, it was found that terminally differentiated CD4 + T cell absolute count is a protective factor for CLL. Immune traits with CRs between both types of leukemia included "CD62L-plasmacytoid dendritic cell %," "plasmacytoid dendritic cell absolute count," "CD11c on granulocytes," "HLA DR + CD8 + T cell %lymphocytes," "HLA DR + CD8 + T cell %," "HLA DR + T cell %," "CD28 on CD28 + CD45RA + CD8 + T cells," "HLA DR + CD4 + T cell absolute count," and "CD45RA- CD28- CD8 + T cell absolute count."
conclusionsThe results of this investigation reveal that leukemia closely relates to specific types of immune cells. Our findings provide a scientific basis for further investigations into factors that will improve immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.